Contact Us

If you have a non-emergency, product-related question, please call Mallinckrodt Medical Information at 1-800-778-7898 or e-mail us at medinfo@mallinckrodt.com.

Alternatively, a suspected adverse event may be reported to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program by phone at 1-800-FDA-1088, by fax at 1-800-FDA-0178, or by mail using Form 3500 available at http://www.fda.gov/medwatch/index.html.

For questions regarding insurance or reimbursement coverage for Acthar, please call the Acthar Support & Access Program at 1-888-435-2284.

IMPORTANT SAFETY INFORMATION

SEE More

Contraindications

  • Acthar should never be administered intravenously
  • Administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of Acthar
  • Acthar is contraindicated where congenital infections are suspected in infants
  • Acthar is contraindicated in patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction or sensitivity to proteins of porcine origins

INDICATIONS

SEE More

H.P. Acthar® Gel (repository corticotropin injection) is an adrenocorticotropic hormone (ACTH) analogue used for:

  • Treatment during an exacerbation or as maintenance therapy in selected cases of systemic dermatomyositis (polymyositis)
  • Treatment during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus
  • The treatment of symptomatic sarcoidosis
  • Adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)